1,201 Humana Inc. $HUM Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA trimmed its position in Humana Inc. (NYSE:HUM) by 1.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 65,811 shares of the insurance provider’s stock after selling 1,201 shares during the period. Pictet Asset Management Holding SA owned approximately 0.05% of Humana worth $25,112,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Parallel Advisors LLC grew its position in Humana by 21.2% in the third quarter. Parallel Advisors LLC now owns 1,746 shares of the insurance provider’s stock valued at $666,000 after purchasing an additional 305 shares in the last quarter. Alta Advisers Ltd acquired a new position in shares of Humana during the 3rd quarter worth about $336,000. Ascent Group LLC boosted its stake in shares of Humana by 19.5% during the 3rd quarter. Ascent Group LLC now owns 710 shares of the insurance provider’s stock worth $271,000 after buying an additional 116 shares during the last quarter. Rakuten Investment Management Inc. grew its holdings in shares of Humana by 9.7% in the 3rd quarter. Rakuten Investment Management Inc. now owns 21,551 shares of the insurance provider’s stock valued at $8,337,000 after acquiring an additional 1,914 shares in the last quarter. Finally, Third View Private Wealth LLC bought a new position in shares of Humana in the 3rd quarter valued at about $264,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Up 1.9%

Humana stock opened at $446.33 on Thursday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.65 and a quick ratio of 1.74. The company’s 50-day moving average is $406.79 and its 200-day moving average is $314.80. The firm has a market capitalization of $53.60 billion, a PE ratio of 43.42, a P/E/G ratio of 2.30 and a beta of 0.65. Humana Inc. has a fifty-two week low of $163.11 and a fifty-two week high of $456.50.

Humana (NYSE:HUM) last issued its earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.30. Humana had a net margin of 0.81% and a return on equity of 8.50%. The business had revenue of $41.16 billion during the quarter, compared to the consensus estimate of $40.87 billion. During the same period last year, the business posted $3.24 EPS. Humana’s revenue was up 26.1% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.500- EPS. Sell-side analysts anticipate that Humana Inc. will post 9.56 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be given a $0.8850 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Thursday, December 24th. Humana’s dividend payout ratio (DPR) is presently 34.44%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on HUM shares. Wolfe Research reiterated an “outperform” rating and set a $450.00 target price on shares of Humana in a report on Monday, August 24th. Truist Financial increased their price target on Humana from $415.00 to $475.00 and gave the company a “hold” rating in a research report on Monday, October 12th. HSBC downgraded Humana to a “hold” rating in a research note on Thursday, July 30th. Cantor Fitzgerald boosted their price target on Humana from $460.00 to $495.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, Deutsche Bank began coverage on Humana in a research note on Thursday, July 30th. They set a “hold” rating on the stock. Twenty-one research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Humana presently has a consensus rating of “Moderate Buy” and an average price target of $472.17.

Key Stories Impacting Humana

Here are a few of the latest stories about HUM:

• Positive Sentiment: Humana’s new oncology model, developed with Evolent and American Oncology Network, aims to reduce prior-authorization delays and administrative work while using data analytics to support value-based care. Investors may see the initiative as a way to improve care coordination and control costs. Article: New oncology model from Humana, Evolent and American Oncology Network
• Positive Sentiment: Several analysts have lifted price targets following the earnings update. JPMorgan raised its target to $484, while TD Cowen increased its target to $430, reflecting improved expectations even as the firms retained neutral or hold ratings. Article: JPMorgan raises Humana price target
• Negative Sentiment: TD Cowen’s $430 target remains below the cited share price, and its Hold rating suggests the firm sees limited near-term upside at current levels. Article: TD Cowen raises Humana price target

About Humana

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.